Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Active, not recruiting Phase 2 Interventional

Efficacy, Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of BIA 28-6156 in GBA-PD

ClinicalTrials.gov ID: NCT05819359

Public ClinicalTrials.gov record NCT05819359. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Oct 24, 2026, 12:17 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of BIA 28-6156 in Subjects With Parkinson's Disease With a Pathogenic Variant in the Glucocerebrosidase (GBA1) Gene

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

The purpose of this randomized, double-blind, placebo-controlled study is to assess the efficacy of BIA 28-6156 over placebo in delaying clinical meaningful motor progression over 78 weeks in subjects with Parkinson's disease who have a pathogenic variant in the glucocerebrosidase 1 (GBA1) gene (GBA-PD).

Study identification

NCT ID
NCT05819359
Recruitment status
Active, not recruiting
Study type
Interventional
Phase
Phase 2
Lead sponsor
Bial R&D Investments, S.A.
Industry
Enrollment
237 participants

Conditions and interventions

Eligibility (public fields only)

Age range
35 Years to 80 Years
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Mar 31, 2023 (Actual)
Primary completion
Apr 2, 2026 (Actual)
Completion
Jul 31, 2026 (Estimated)
Last update posted
May 13, 2026

2023 – 2026

United States locations

U.S. sites
43
U.S. states
23
U.S. cities
33
Facility City State ZIP Site status
Barrow Neurological Institute Phoenix Arizona 85013 —
University of California San Diego La Jolla California 92037 —
Cedars-Sinai Los Angeles California 90048 —
University of Colorado Aurora Colorado 80045 —
Parkinson's Center and Movement Disorders of Boca Raton Boca Raton Florida 33486 —
University of Miami, Dept. of Neurology Miami Florida 33136 —
Renstar Medical Research Ocala Florida 34470 —
Morehouse School of Medicine Atlanta Georgia 30310 —
Northwestern University Chicago Illinois 60611 —
Rush University Medical Center Chicago Illinois 60612 —
University of Iowa Hospitals and Clinics Iowa City Iowa 52242 —
University of Kansas Medical Center Kansas City Kansas 66103 —
University of Kentucky Lexington Kentucky 40536 —
University of Maryland Medical Center Baltimore Maryland 21201 —
Baylor University Medical Center Baltimore Maryland 21287 —
The Johns Hopkins University School of Medicine Baltimore Maryland 21287 —
Massachusetts General Hospital Boston Massachusetts 02114 —
Beth Israel Deaconess Medical Center Boston Massachusetts 02115 —
Quest Research Institute, LLC Farmington Hills Michigan 48334 —
Mayo Clinic Rochester Minnesota 55905 —
Struthers Parkinson's Center- East Saint Paul Minnesota 55130 —
Park Nicollet Struther's Parkinson's Center (Struthers Parkinsons Center at HealthPartners) Saint Paul Minnesota 55427 —
Robert Wood Johnson Medical School New Brunswick New Jersey 08901 —
Icahn School of Medicine at Mount Sinai Beth Israel New York New York 10003 —
Weil Cornell Medical Center New York New York 10021 —
Columbia University Medical Center New York New York 10032 —
Northwell Health Physician Partners New York New York 10075-1851 —
Northwell Health New York New York 10075 —
University of Rochester Neurology Rochester New York 14642 —
Cleveland Clinic Foundation Cleveland Ohio 44195 —
University Hospitals Cleveland Medical Center South Euclid Ohio 44121 —
Univerity of Toledo Toledo Ohio 43614 —
Oregon Health and Science University Portland Oregon 97239 —
Parkinson's Disease and Movement Disorders Cente at University of Pennyslvania Philadelphia Pennsylvania 19107 —
Thomas Jefferson University Philadelphia Pennsylvania 19107 —
MUSC Charleston South Carolina 29425 —
Vanderbilt Medical Center Nashville Tennessee 37232 —
Baylor College of Medicine Houston Texas 77030 —
University of Texas Health Science Center - San Antonio San Antonio Texas 78229 —
Intermountain Healthcare Salt Lake City Utah 84107 —
Evergreen Neuroscience Institute Kirkland Washington 98034 —
University of Washington Seattle Washington 98195 —
Inland Northwest Research Spokane Washington 99202 —

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 52 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT05819359, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted May 13, 2026 · Synced Oct 24, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete public registry record, listed eligibility criteria, and available contact information for NCT05819359 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →